Wang QF, Li ZW, Zhou HF, Zhu KZ, Wang YJ, Wang YQ, Zhang YW. Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(6): 2380-2393 [DOI: 10.4251/wjgo.v16.i6.2380]
Corresponding Author of This Article
Yue-Wei Zhang, Academic Research, Chief Doctor, Department of Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, No. 168 Litang Road, Beijing 102218, China. zhangyuewei1121@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Qi-Feng Wang, Ya-Jing Wang, Ya-Qin Wang, Yue-Wei Zhang, Department of Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing 102218, China
Qi-Feng Wang, Zong-Wei Li, Hai-Feng Zhou, Kun-Zhong Zhu, Department of Hepatobiliary and Pancreatic Surgery, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
Co-corresponding authors: Ya-Qin Wang and Yue-Wei Zhang.
Author contributions: Wang QF drafted the manuscript and conception; Li ZW, Zhou HF, and Zhu KZ performed the literature search, and design; Wang YJ collected and assessed the data; Wang YQ and Zhang YW were contributed equally to this work responsible for the conception of the study, final editing, and review of the manuscript and as co-corresponding authors; all authors contributed to the article and approved the submitted version.
Supported bythe Research Fund of Beijing Tsinghua Changgung Hospital, No. 12021C11016.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yue-Wei Zhang, Academic Research, Chief Doctor, Department of Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, No. 168 Litang Road, Beijing 102218, China. zhangyuewei1121@sina.com
Received: December 18, 2023 Revised: January 19, 2024 Accepted: April 3, 2024 Published online: June 15, 2024 Processing time: 179 Days and 23.1 Hours
Abstract
Hepatic artery infusion chemotherapy (HAIC) has good clinical efficacy in the treatment of advanced hepatocellular carcinoma (HCC); however, its efficacy varies. This review summarized the ability of various markers to predict the efficacy of HAIC and provided a reference for clinical applications. As of October 25, 2023, 51 articles have been retrieved based on keyword predictions and HAIC. Sixteen eligible articles were selected for inclusion in this study. Comprehensive literature analysis found that methods used to predict the efficacy of HAIC include serological testing, gene testing, and imaging testing. The above indicators and their combined forms showed excellent predictive effects in retrospective studies. This review summarized the strategies currently used to predict the efficacy of HAIC in middle and advanced HCC, analyzed each marker's ability to predict HAIC efficacy, and provided a reference for the clinical application of the prediction system.
Core Tip: Hepatic artery infusion chemotherapy (HAIC) has good clinical efficacy and high safety, and it has become one of the main treatment options for patients with intermediate to advanced hepatocellular carcinoma (HCC). Through predicting the prognosis of HAIC, appropriate patients can be screened for HAIC, and the overall efficacy of HAIC in HCC patients can improve. This review summarized the strategies currently used to predict the efficacy of HAIC in middle and advanced HCC, analyzed each marker's ability to predict HAIC efficacy, and provided a reference for the clinical selection of an appropriate HAIC prediction modality.
